Evaluating Patient-Reported Outcomes in MAGNITUDE Trial for mCRPC

Kim N. Chi, MD, FRCPC, medical oncologist, vice president, chief medical officer, British Columbia Cancer, professor, Division of Medical Oncology, University of British Columbia, discusses the significance of the phase 3 MAGNITUDE trial (NCT03748641), including its evaluation on patient-reported outcomes, in patients with BRCA1/2-altered metastatic castration-resistant prostate cancer (mCRPC).

In the MAGNITUDE trial, patients with mCRPC were treated with niraparib plus abiraterone acetate and prednisone. Prior findings from the study showed that the combination elicited improved rates of radiographic progression-free survival among these patients.

During the ASCO GU 2024, researchers, including Chi, presented data on pain, health-related quality of life (QOL), and adverse events (AEs) in the MAGNITUDE trial. They found that the combination did not worsen pain or QOL compared with those treated with placebo, and rates of AEs were minimal across both groups.

In addition, Chi discusses how the insights on patient-reported outcomes observed in this study differ from traditional clinical end points.

Transcription:

0:09 | For any clinical trial or new treatment, although it is important that our usual primary end points of radiographic progression-free survival and overall survival are met, we also want to see from a patient perspective how they are doing on the treatments, both from an [adverse] effect point of view [and] also a symptom improvement point of view.

0:31 | Traditional clinical end points tend to be things like response rate, which is a measurement on a CT scan, a PSA test, which is a lab measurement, or survival, such as how long somebody lives, and these are important. However, they are not necessarily from the patient perspective and from the patient perspective, we want to know how they are doing on it. This is the patient's voice in the treatment.

REFERENCE:

1. Rathkopf DE, Roubaud G, Chi KN, et al. Patient-reported outcomes (PRO) in patients (pts) with BRCA1/2-altered metastatic castration-resistant prostate cancer (mCRPC) receiving niraparib (NIRA) with abiraterone acetate and prednisone (AAP): Results from MAGNITUDE study. J Clin Oncol. 2024;42(Suppl 4):105. doi:10.1200/JCO.2024.42.4_suppl.105